Javascript must be enabled to continue!
2090 EBV Colitis With Fulminate Ulcerative Colitis: A Clinical Dilemma
View through CrossRef
INTRODUCTION:
Epstein-Barr virus (EBV) is a virus of the herpes family. EBV can be detected in the gastrointestinal tissue of patients with inflammatory bowel disease(IBD). However, the clinical significance of EBV colitis in ulcerative colitis (UC) is unclear. We present an interesting and rare case of EBV colitis in a patient with fulminant UC.
CASE DESCRIPTION/METHODS:
A 73-year-old male with history of hypertension and recent diagnosis of UC who was doing well on mesalamine developed a flare with acute onset diarrhea, abdominal pain, and rectal bleeding. Stool tests were negative for C difficile and common bacterial and viral pathogens. Fecal calprotectin was >2000 μg/mg, and CT abdomen/pelvis was notable for thickened colon walls. Colonoscopy showed moderate inflammation with aphthous ulcerations throughout the colon with sparing of the cecum. Patient was started on oral steroids and transitioned to adalimumab. He continued to have weight loss and diarrhea and was switched to vedolizumab after two months. Due to continued symptoms, repeat colonoscopy 6 months later showed severe inflammation with confluent ulcerations in continuous and circumferential pattern from rectum to transverse colon (Figure 1). Laboratory workup was notable for anemia (hgb 9.0 g/dL), hypoalbuminemia (2.9 g/dL) and high C-reactive protein (3.22 mg/dL). Patient was admitted for IV steroids. Infliximab was started on day 5 due to no improvement in symptoms. At this time biopsies obtained during colonoscopy were reported to be positive for EBV-encoded small RNA by in-situ hybridization (Figure 2). EBV was also detected in whole blood by PCR. IV gancyclovir was started. After 7 days of treatment with gancyclovir, repeat flexible sigmoidoscopy showed no significant improvement. Immunostains for EBV, CMV, and HSV were negative. EBV PCR declined (60,000 to 30,000 IU/ml). A subtotal abdominal colectomy with end ileostomy and rectal stump was eventually performed without any complications. Patient gained weight and did well post operatively.
DISCUSSION:
EBV colitis with fulminant UC is rare. The clinical implication of EBV colitis and treatment benefits are unclear. In addition, there is lack of a standard therapy for EBV infection with case reports showing improvement with gancyclovir. Our case of true EBV colitis with fulminant UC illustrates the importance of considering a superimposed infection in patients with IBD refractory to steroids and immunosuppressive therapy early in the course of the disease to prevent progression.
Ovid Technologies (Wolters Kluwer Health)
Title: 2090 EBV Colitis With Fulminate Ulcerative Colitis: A Clinical Dilemma
Description:
INTRODUCTION:
Epstein-Barr virus (EBV) is a virus of the herpes family.
EBV can be detected in the gastrointestinal tissue of patients with inflammatory bowel disease(IBD).
However, the clinical significance of EBV colitis in ulcerative colitis (UC) is unclear.
We present an interesting and rare case of EBV colitis in a patient with fulminant UC.
CASE DESCRIPTION/METHODS:
A 73-year-old male with history of hypertension and recent diagnosis of UC who was doing well on mesalamine developed a flare with acute onset diarrhea, abdominal pain, and rectal bleeding.
Stool tests were negative for C difficile and common bacterial and viral pathogens.
Fecal calprotectin was >2000 μg/mg, and CT abdomen/pelvis was notable for thickened colon walls.
Colonoscopy showed moderate inflammation with aphthous ulcerations throughout the colon with sparing of the cecum.
Patient was started on oral steroids and transitioned to adalimumab.
He continued to have weight loss and diarrhea and was switched to vedolizumab after two months.
Due to continued symptoms, repeat colonoscopy 6 months later showed severe inflammation with confluent ulcerations in continuous and circumferential pattern from rectum to transverse colon (Figure 1).
Laboratory workup was notable for anemia (hgb 9.
0 g/dL), hypoalbuminemia (2.
9 g/dL) and high C-reactive protein (3.
22 mg/dL).
Patient was admitted for IV steroids.
Infliximab was started on day 5 due to no improvement in symptoms.
At this time biopsies obtained during colonoscopy were reported to be positive for EBV-encoded small RNA by in-situ hybridization (Figure 2).
EBV was also detected in whole blood by PCR.
IV gancyclovir was started.
After 7 days of treatment with gancyclovir, repeat flexible sigmoidoscopy showed no significant improvement.
Immunostains for EBV, CMV, and HSV were negative.
EBV PCR declined (60,000 to 30,000 IU/ml).
A subtotal abdominal colectomy with end ileostomy and rectal stump was eventually performed without any complications.
Patient gained weight and did well post operatively.
DISCUSSION:
EBV colitis with fulminant UC is rare.
The clinical implication of EBV colitis and treatment benefits are unclear.
In addition, there is lack of a standard therapy for EBV infection with case reports showing improvement with gancyclovir.
Our case of true EBV colitis with fulminant UC illustrates the importance of considering a superimposed infection in patients with IBD refractory to steroids and immunosuppressive therapy early in the course of the disease to prevent progression.
Related Results
The Nuclear Lamina Binds the EBV Genome During Latency and Regulates Viral Gene Expression
The Nuclear Lamina Binds the EBV Genome During Latency and Regulates Viral Gene Expression
ABSTRACTThe Epstein Barr virus (EBV) infects almost 95% of the population worldwide. While typically asymptomatic, EBV latent infection is associated with several malignancies of e...
Risk factors for post‐transplant Epstein‐Barr virus events in pediatric recipients of hematopoietic stem cell transplants
Risk factors for post‐transplant Epstein‐Barr virus events in pediatric recipients of hematopoietic stem cell transplants
AbstractBackgroundEpstein‐Barr virus (EBV) can cause severe disease following hematopoietic stem cell transplant (HSCT), including post‐transplant lymphoproliferative disorder (PTL...
Abstract 3749: Oncogenic role of Epstein-Barr virus lnc-BARTs in EBV associated tumors
Abstract 3749: Oncogenic role of Epstein-Barr virus lnc-BARTs in EBV associated tumors
Abstract
While majority of humans infected with Epstein-Barr virus (EBV) is asymptomatic for whole life, EBV is found to associate with several human cancers, includ...
Osteopathic Primary Care Treatment Options for Ulcerative Colitis
Osteopathic Primary Care Treatment Options for Ulcerative Colitis
Ulcerative colitis is a multifactorial, chronic inflammatory disease of the bowel that can cause physical, social and emotional injury to the patient. While perhaps not always maki...
Case–Control Analysis of 48 Pediatric Infection-Associated Hemophagocytic Lymphohistiocytosis
Case–Control Analysis of 48 Pediatric Infection-Associated Hemophagocytic Lymphohistiocytosis
Abstract
Objective
To analyze the clinical characteristics, laboratory data and treatment plan of hemophagocytic lymphohistiocytosis (HLH).
...
Transfusion‐related Epstein‐Barr virus (EBV) infection: A multicenter prospective cohort study among pediatric recipients of hematopoietic stem cell transplants (TREASuRE study)
Transfusion‐related Epstein‐Barr virus (EBV) infection: A multicenter prospective cohort study among pediatric recipients of hematopoietic stem cell transplants (TREASuRE study)
AbstractBackgroundEpstein‐Barr virus (EBV) is carried in the blood of most adults, and transfusion‐related infections have been reported. EBV is particularly deleterious in immunos...
Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
Background: Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) characterized by intestinal inflammation confined to the superficial mucosal layer. Mesalazi...
Abstract 3500: Epstein-Barr virus BART noncoding RNAs modulate host gene expression for virus latency leading to oncogenesis in epithelial cells
Abstract 3500: Epstein-Barr virus BART noncoding RNAs modulate host gene expression for virus latency leading to oncogenesis in epithelial cells
Abstract
Epstein-Barr virus (EBV) efficiently establishes and maintains a state of latency in resting B cells, with persistent asymptomatic infections occurring in m...

